Nikolaj Skydsgaard

Copenhagen

Journalist at TV 2

Journalist @ TV 2. +45 21638000 (phone, WhatsApp, Signal).

Featured in: Favicon

reuters.com Favicon

msn.com

businessinsider.com Favicon

dailymail.co.uk Favicon

mirror.co.uk Favicon

terra.com.br Favicon

independent.co.uk Favicon

yahoo.com (+14) Favicon

aol.com

smh.com.au + 76 more

Articles

Novo eyes other health benefits from weight-loss drug Wegovy after major trial

Aug 10, 2023 | msn.com | Nikolaj Skydsgaard |Jacob Gronholt-Pedersen

The island’s health ministry began discharging the treatment on 8 August – long celebrated as International Cat Day – in what is hoped will be the beginning of the end of the disease that has struck the Mediterranean country’s feline population. “We have taken stock of 500 boxes of medication,” Christodoulos Pipis, the government’s veterinary services director, told the Guardian. “This is the first batch of 2,000 packages that will be made available.
Novo Nordisk CEO sees US supply curbs on weight-loss drug Wegovy into 2024

Aug 10, 2023 | srnnews.com | Nikolaj Skydsgaard |Jacob Gronholt-Pedersen

Novo Nordisk CEO sees US supply curbs on weight-loss drug Wegovy into 2024 By Nikolaj Skydsgaard and Jacob Gronholt-PedersenCOPENHAGEN (Reuters) -Novo Nordisk’s limits on U.S. supplies of starter doses of its hugely popular Wegovy weight-loss drug will last into next year even as the Danish drugmaker spends billions boosting output, its CEO told Reuters on Thursday.
Novo Nordisk amplía las limitaciones a la oferta de Wegovy en EEUU

Aug 10, 2023 | msn.com | Nikolaj Skydsgaard

COPENHAGUE, 10 ago (Reuters) - Novo Nordisk seguirá restringiendo en los próximos trimestres el suministro en Estados Unidos de las dosis iniciales de su popular medicamento para adelgazar Wegovy, según anunció el jueves la empresa, que lucha por mantener el ritmo de la creciente demanda estadounidense. La noticia se conoció cuando la farmacéutica danesa elevó por segunda vez sus previsiones de beneficios y ventas para todo el año.
Novo eyes other health benefits from weight-loss drug Wegovy after major trial

Aug 10, 2023 | reuters.com | Nikolaj Skydsgaard |Jacob Gronholt-Pedersen

By Nikolaj Skydsgaard, Jacob Gronholt-PedersenCOPENHAGEN (Reuters) - Novo Nordisk hopes to show additional health benefits from taking its hugely popular drug Wegovy, apart from losing weight and cutting the risk of heart disease, its drug development executive told Reuters on Thursday. The Danish drugmaker this week published headline results from its major SELECT trial, which showed that the weekly injection decreased the risk of heart attacks and strokes by 20%.
Supply Limits Extended on Weight-Loss Drug Wegovy

Aug 10, 2023 | newsmax.com | Nikolaj Skydsgaard

Novo Nordisk will continue to restrict U.S. supplies of starter doses of its hugely popular Wegovy weight-loss drug most likely into 2024, it said on Thursday, as the company struggles to keep up with soaring U.S. demand. The news came as the Danish drugmaker raised its full-year profit and sales forecasts for a second time.
Novo Nordisk amplía las limitaciones a la oferta de Wegovy en EEUU

Aug 10, 2023 | msn.com | Nikolaj Skydsgaard

Gestionar las preferencias de consentimientoCookies necesarias para realizar funciones esenciales del sitio web. Estas cookies son necesarias para que nuestros sitios web funcionen.
Novo Nordisk amplía las limitaciones a la oferta de Wegovy en EEUU

Aug 10, 2023 | es-us.finanzas.yahoo.com | Nikolaj Skydsgaard

Por Nikolaj SkydsgaardCOPENHAGUE, 10 ago (Reuters) - Novo Nordisk seguirá restringiendo en los próximos trimestres el suministro en Estados Unidos de las dosis iniciales de su popular medicamento para adelgazar Wegovy, según anunció el jueves la empresa, que lucha por mantener el ritmo de la creciente demanda estadounidense. La noticia se conoció cuando la farmacéutica danesa elevó por segunda vez sus previsiones de beneficios y ventas para todo el año.
Novo Nordisk extends U.S. supply curbs on weight-loss drug Wegovy

Aug 10, 2023 | finance.yahoo.com | Nikolaj Skydsgaard

By Nikolaj SkydsgaardCOPENHAGEN (Reuters) -Novo Nordisk will continue to restrict U.S. supplies of starter doses of its hugely popular Wegovy weight-loss drug in the coming quarters, it said on Thursday, as the company struggles to keep up with soaring U.S. demand. The news came as the Danish drugmaker raised its full-year profit and sales forecasts for a second time.
Novo's Wegovy shows heart benefit alongside weight loss in trial By Reuters

Aug 9, 2023 | entrepreneurnews.co.uk | Johnathan Brickson |Maggie Fick |Nikolaj Skydsgaard

© Reuters. FILE PHOTO: A selection of injector pens for the Wegovy weight loss drug are shown in this photo illustration in Chicago, Illinois, U.S., March 31, 2023.
Why are Sweden and Denmark having a crisis over the Koran?

Aug 8, 2023 | japantoday.com | Nikolaj Skydsgaard |Jacob Gronholt-Pedersen

Anti-Islam activists in Denmark and Sweden have burnt and damaged several copies of the Koran in recent months, prompting outrage in the Muslim world and demands the Nordic governments ban such acts. Both governments have condemned the burnings and said they are considering new laws that could stop them. But domestic critics say freedom of speech and expression is protected in their constitutions and any move to change that would undermine prized freedoms. WHO IS BURNING THE KORAN AND WHY?